Diurnal is a rare breed amongst British smaller companies in the life sciences sector, and indeed globally, in that within a little over two years since listing it has achieved commercialisation in Europe of an authorised medicine for a rare paediatric condition. From within its rich pipeline of endocrine focussed candidates, Diurnal has also completed a pivotal Phase 3 study in another late stage candidate with a regulatory pathway defined suggesting that a second product could be generating
26 Sep 2019
Well on the way to becoming a major player in endocrine diseases
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Well on the way to becoming a major player in endocrine diseases
- Published:
26 Sep 2019 -
Author:
Derren Nathan -
Pages:
12
Diurnal is a rare breed amongst British smaller companies in the life sciences sector, and indeed globally, in that within a little over two years since listing it has achieved commercialisation in Europe of an authorised medicine for a rare paediatric condition. From within its rich pipeline of endocrine focussed candidates, Diurnal has also completed a pivotal Phase 3 study in another late stage candidate with a regulatory pathway defined suggesting that a second product could be generating